Allogeneic CAR T data keep CRISPR Therapeutics competitive

With efficacy holding steady and no new serious safety issues, the latest data for CTX110 puts the allogeneic CAR T cell therapy from CRISPR Therapeutics in a position to compete with autologous products, but it’s not enough to provide relief for investors on edge since a competing program sparked safety concerns last week.

CRISPR Therapeutics AG (NASDAQ:CRSP) was off 8% to $94 in after-hours trading on Tuesday after announcing that the CD19-targeting allogeneic CAR T cell therapy led to an overall response rate of 58% in the intent-to-treat population of 24 large B cell lymphoma patients, a complete response of 38% and a favorable safety profile...